Inhibitor Therapeutics (INTI) Stock Chart & Stock Price History $0.06 +0.00 (+5.18%) As of 05/22/2025 09:30 AM Eastern Add Compare Share Share Chart Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock Inhibitor Therapeutics Stock Price Performance The Inhibitor Therapeutics (INTI) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 41.10%, with a year-to-date return of -2.00%. In the past month, the stock has increased 32.66%, reflecting recent market activity. As of the latest close, Inhibitor Therapeutics traded at $0.06 with a market cap of $10.17 million and volume of 20,677 shares. Five years ago, the stock traded at $0.04, representing a 40.24% increase over that period. At the time, it had a market cap of $16.67 million and a volume of 1,000 shares. Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+5.18%1 Month Performance+32.66%3 Month Performance-10.62%Year-To-Date Performance-2.00%1 Year Performance-41.10%5 Year Performance+40.24% INTI Stock Chart for Friday, May, 23, 2025 INTI Chart by TradingView Inhibitor Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/23/2025$0.06$0.06$0.06$0.0620,677 shs$10.17 million05/22/2025$0.06$0.06+5.18%$0.06$0.0620,677 shs$10.17 million05/16/2025$0.06$0.06$0.06$0.068,000 shs$9.66 million05/15/2025$0.06$0.06-6.67%$0.06$0.068,000 shs$9.66 million05/14/2025$0.06$0.06$0.06$0.032,000 shs$10.35 million05/13/2025$0.04$0.06+36.36%$0.06$0.061,500 shs$10.35 million05/12/2025$0.06$0.04-21.57%$0.06$0.0427,000 shs$7.59 million05/09/2025$0.05$0.06+19.36%$0.06$0.0455,763 shs$9.68 million05/08/2025$0.04$0.05+27.72%$0.05$0.051,000 shs$8.11 million05/07/2025$0.05$0.04-26.40%$0.04$0.0460,300 shs$6.35 million Get the Latest News and Ratings for INTI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/02/2025$0.05$0.05$0.05$0.0490,426 shs$8.63 million05/01/2025$0.06$0.05-18.83%$0.05$0.0490,426 shs$8.63 million04/30/2025$0.04$0.06+40.00%$0.06$0.042,000 shs$10.63 million04/29/2025$0.05$0.04-11.82%$0.07$0.0425,100 shs$7.59 million04/28/2025$0.06$0.05-16.28%$0.05$0.0510,000 shs$8.61 million04/25/2025$0.05$0.06+21.38%$0.06$0.0529,000 shs$10.29 million04/24/2025$0.04$0.05+10.59%$0.05$0.0522,000 shs$8.47 million04/23/2025$0.05$0.04-11.02%$0.05$0.04108,140 shs$7.66 million04/22/2025$0.04$0.05+17.14%$0.05$0.0430,000 shs$8.61 million Related Companies Prelude Therapeutics Stock Chart Quince Therapeutics Stock Chart Rani Therapeutics Stock Chart Spero Therapeutics Stock Chart Mana Capital Acquisition Stock Chart Barinthus Biotherapeutics Stock Chart Acrivon Therapeutics Stock Chart OS Therapies Stock Chart Lantern Pharma Stock Chart Aligos Therapeutics Stock Chart Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:INTI) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
